Strategies for Advanced Oncolytic Virotherapy: Current Technology Innovations and Clinical Approaches
文献类型：期刊论文
| 作者 | Ji, Qing4; Wu, Yuchen5; Albers, Andreas1,2,3; Fang, Meiyu4; Qian, Xu5 |
| 刊名 | PHARMACEUTICS
 |
| 出版日期 | 2022-09-01 |
| 卷号 | 14 |
| 关键词 | oncolytic viruses nanotechnology oncolytic virotherapy immunotherapy melanoma head and neck cancer |
| DOI | 10.3390/pharmaceutics14091811 |
| 通讯作者 | Fang, Meiyu(fangmy@zjcc.org.cn) ; Qian, Xu(qian_michelle2014@163.com) |
| 英文摘要 | Oncolytic virotherapy is a type of nanomedicine with a dual antitumor mechanism. Viruses are engineered to selectively infect and lyse cancer cells directly, leading to the release of soluble antigens which induce systemic antitumor immunity. Representative drug Talimogene laherparepvec has showed promising therapeutic effects in advanced melanoma, especially when combined with immune checkpoint inhibitors with moderate adverse effects. Diverse viruses like herpes simplex virus, adenovirus, vaccina virus, and so on could be engineered as vectors to express different transgenic payloads, vastly expanding the therapeutic potential of oncolytic virotherapy. A number of related clinical trials are under way which are mainly focusing on solid tumors. Studies about further optimizing the genome of oncolytic viruses or improving the delivering system are in the hotspot, indicating the future development of oncolytic virotherapy in the clinic. This review introduces the latest progress in clinical trials and pre-clinical studies as well as technology innovations directed at oncolytic viruses. The challenges and perspectives of oncolytic virotherapy towards clinical application are also discussed. |
| WOS关键词 | HERPES-SIMPLEX-VIRUS ; IMMUNOTHERAPEUTIC VACCINIA VIRUS ; CARRYING P53 GENE ; PEXA-VEC JX-594 ; PHASE-I TRIAL ; CAR-T CELL ; TALIMOGENE LAHERPAREPVEC ; INTRAVENOUS DELIVERY ; DOSE-ESCALATION ; SINGLE-ARM |
| 资助项目 | National Key R&D Program of China[2019YFA0905800] ; Natural Science Foundation of Zhejiang Province[LGF21H200002] ; Internal Talent Program (Under Forty) of Zhejiang Cancer Hospital |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000857534100001 |
| 出版者 | MDPI |
| 资助机构 | National Key R&D Program of China ; Natural Science Foundation of Zhejiang Province ; Internal Talent Program (Under Forty) of Zhejiang Cancer Hospital |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/128976]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Fang, Meiyu; Qian, Xu |
| 作者单位 | 1.Charite Univ Med Berlin, Dept Otolaryngol Head & Neck Surg, Berlin Inst Hlth, D-13353 Berlin, Germany 2.Humboldt Univ, D-13353 Berlin, Germany 3.Free Univ Berlin, D-13353 Berlin, Germany 4.Univ Chinese Acad Sci, Dept Rare & Head & Neck Oncol,Chinese Acad Sci, Key Lab Head & Neck Canc Translat Res Zhejiang Pr, Canc Hosp,Zhejiang Canc Hosp,Inst Basic Med & Can, Hangzhou 310022, Peoples R China 5.Univ Chinese Acad Sci, Dept Clin Lab, Zhejiang Canc Hosp, Canc Hosp,Inst Basic Med & Canc IBMC,Chinese Acad, Hangzhou 310022, Peoples R China |
| 推荐引用方式 GB/T 7714 | Ji, Qing,Wu, Yuchen,Albers, Andreas,et al. Strategies for Advanced Oncolytic Virotherapy: Current Technology Innovations and Clinical Approaches[J]. PHARMACEUTICS,2022,14. |
| APA | Ji, Qing,Wu, Yuchen,Albers, Andreas,Fang, Meiyu,&Qian, Xu.(2022).Strategies for Advanced Oncolytic Virotherapy: Current Technology Innovations and Clinical Approaches.PHARMACEUTICS,14. |
| MLA | Ji, Qing,et al."Strategies for Advanced Oncolytic Virotherapy: Current Technology Innovations and Clinical Approaches".PHARMACEUTICS 14(2022). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。